Why cutting GLP-1 benefits could be a costly mistake for companies

Employers are reducing coverage for GLP-1 medications like Ozempic and Wegovy to cut healthcare costs, but a study suggests this may backfire. Research from the National Bureau of Economic Research found GLP-1 treatments reduced long-term sick leave by 17.3% and generated $866 in annual productivity gains per worker in Denmark. However, U.S. employers face different healthcare systems and higher costs, complicating direct comparisons.